Cuplike nuclei in B-cell acute lymphoblastic leukemia with DUX4 rearrangement
Shoot for 150-160 chars
Related Articles
Randy Moss’ Rare GI Cancer: Here’s What to Know
Hall of Fame football player recently revealed his cholangiocarcinoma diagnosis
Delivering bad news in clinical hematology: a personal perspective | Published in Clinical Hematology International
By Mohamad Mohty, Finn Bo Petersen & 1 more. Conversations that require delivering bad news to patients and families in clinical hematology often involves the…
Climate change: defeating misinformation with trusted knowledge
Finland’s first planetary health physician is prescribing “walking home barefoot through nature” (doi:10.1136/bmj.q2093).1 Meanwhile, only 27% of Republicans who are registered to vote in the…
Former trans charity boss to defy ban on puberty blockers
Anne Trans Healthcare, which was set up by Susie Green, former head of Mermaids, says it will continue to offer ‘legal’ ways to access the…
Puberty blockers banned because of ‘unacceptable safety risk’
Wes Streeting said the decision to indefinitely ban the drugs, which suppress the release of sex hormones, was taken based on advice from medical experts
How to save a fentanyl victim: Key facts about naloxone
Naloxone is an over-the-counter nasal-spray medication that can save an overdose victim by rapidly reversing the effects of fentanyl, heroin and other opioids.
Anatomy of a science meeting: How controversial pesticide research all but vanished from a major conference
During hundreds of sessions, a significant topic went missing: scholarly research on one of Corteva’s products – neonicotinoids.
Myeloma Paper of the Day, December 21st, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, December 21st, suggested by Robert Orlowski / Anne J. Novak, cancer, Hyo Jin Kim, Jonas Paludo, Jordan E. Krull, Jose…
Yoga has many health benefits as you age – but is it also the secret to longevity?
Yoga is shown to benefit mental health, reduce risk of age-related diseases and even protect cognitive function.
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1) – PubMed
Patients with MIBC treated with AMVAC followed by a risk-adapted approach to local consolidation achieved a 2-year MFS rate of 73%. The primary end point…
